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Introduction
HIV-1 is a cytopathic retrovirus that is the primary
etiological agent of AIDS and related disorders. HIV-1
transcription is directed by a promoter located in the
5¢ long terminal repeat (LTR) of the integrated provi-
rus, and is controlled by cellular factors that bind to
the multiple cis-regulatory elements located in the
LTR as well as by the virally encoded Tat protein [1].
In the absence of Tat, transcription of HIV mRNAs
can be initiated but these cannot be efficiently elon-
gated to produce full-length viral RNA genome [2],
making Tat a feasible therapeutic target.
Tat interacts specifically with cyclin T1 (CycT1), a
regulatory partner of cyclin-dependent kinase 9
(CDK9), in the positive transcription elongation factor
(P-TEFb) complex, and, together with CycT1, binds
cooperatively to the transactivation-responsive element
(TAR), in which a bulged RNA loop structure located
at the 5¢ end of the nascent viral RNA transcripts is
used to recruit P-TEFb and promote the transcrip-
tional elongation of HIV [3,4]. Assembly of the Tat–
TAR–P-TEFb complex at the HIV promoter activates
the CDK9 kinase activity, which further autophos-
phorylates P-TEFb and hyperphosphorylates the C-ter-
minal domain of RNA polymerase II [5,6], leading to
formation of processive elongation complexes that syn-
thesize full-length HIV viral mRNA. Interestingly,
murine CycT1, which is very similar to human CycT1
at the amino acid level, could not support HIV-1 tran-
scription [3,7], indicating specificity of the Tat–CycT1
interaction. Moreover, although the nascent P-TEFb
Keywords
cyclin T1; HIV; protein stability; Tat;
transcription
Correspondence
T. Okamoto, Department of Molecular and
Cellular Biology, Nagoya City University
Graduate School of Medical Sciences, 1
Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya,
Aichi 467-8601, Japan
Fax: +81 52 859 1235
Tel: +81 52 853 8204
E-mail: tokamoto@med.nagoya-cu.ac.jp
(Received 2 July 2009, revised 16
September 2009, accepted 5 October
2009)
doi:10.1111/j.1742-4658.2009.07424.x
Transcription from HIV-1 proviral DNA is a rate-determining step for
HIV-1 replication. Interaction between the cyclin T1 (CycT1) subunit of
positive transcription elongation factor b (P-TEFb) and the Tat transacti-
vator protein of HIV-1 is crucial for viral transcription. CycT1 also inter-
acts directly with the transactivation-responsive element (TAR) located on
the 5¢end of viral mRNA, as well as with Tat through the Tat–TAR recog-
nition motif (TRM). These molecular interactions represent a critical step
for stimulation of HIV transcription. Thus, Tat and CycT1 are considered
to be feasible targets for the development of novel anti-HIV therapies. In
this study, we demonstrate that CycT1 is positively involved in the Tat
protein stability. Selective degradation of CycT1 by small interfering
RNA (siRNA) culminated in proteasome-mediated degradation of Tat and
eventual inhibition of HIV-1 gene expression. We noted that the siRNA-
mediated knockdown of CycT1 could inhibit HIV-1 transcription without
affecting cell viability and Tat mRNA levels. These findings clearly indicate
that CycT1 is a feasible therapeutic target, and inactivation or depletion of
CycT1 should effectively inhibit HIV replication by destabilizing Tat and
suppressing Tat-mediated HIV transcription.
Abbreviations
CDK9, cyclin-dependent kinase 9; CycT1, cyclin T1; LTR, long terminal repeat; ponA, ponasteron A; P-TEFb, positive transcription elongation
factor b; siRNA, small interfering RNA; TAR, transactivation responsive element; TRM, Tat–TAR recognition motif.
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complex includes either CycT2a, CycT2b, CycK [5,6]
or CycT1 and CDK9 subunits, only the CycT1 ⁄CDK9
heterodimer acts as an HIV-1 Tat-specific transcription
factor [7,8].
The development of combination therapy using mul-
tiple anti-retroviral drugs for the treatment of HIV-1
infection has led to dramatic therapeutic improvement
of anti-HIV therapy and saved the lives of many HIV-
infected individuals. However, current anti-HIV ther-
apy does not provide an ultimate cure for patients and
may result in drug-resistant viral variants. Therefore,
new antiviral therapeutic or preventive approaches are
urgently required. Specifically, the transactivation
mechanism is an attractive target for the development
of new anti-retroviral drug therapies as Tat is required
for viral gene expression not only during exponential
growth of the virus, but more critically, during activa-
tion of the integrated proviral genomes that give rise
to drug-resistant strains of HIV-1.
Several studies have demonstrated that Tat-mediated
transactivation can be efficiently blocked by various
approaches with Tat as a molecular target, including
use of anti-Tat intrabodies [9], ribozyme-based inacti-
vation of tat mRNA [10], TAR decoys [11], anti-tat
RNA interference [12,13], and others [14–17]. How-
ever, a major limitation of these approaches is the
sequence variation of the tat gene among virus isolates.
Previous reports have shown that RNA interference
can be used to successfully downregulate the expres-
sion of a number of HIV-1 genes, including gag, pol,
vif, nef and tat [12,13,18–20]. These results suggest that
targeting viral factors required for the HIV-1 lifecycle
using small interfering RNA (siRNA) is a viable
method for treating HIV-1 infections. However, the
high mutation rate of HIV leads to viral mutants that
can escape the inhibitory effects of anti-viral siRNAs
[21–23]. Thus, a cellular factor that is essential for viral
replication, such as CycT1, is a feasible target for
antiviral therapy. As CycT1 is fundamental for HIV-1
gene expression, it is an effective target for anti-HIV
drug therapy [24–30]. In this report, we demonstrate
for the first time that downregulation of CycT1 by
siRNA-mediated knockdown also downregulated the
steady-state level of Tat protein, leading to suppression
of HIV-1 transcription.
Results
Downregulation of Tat upon cyclin T1 protein
depletion
To examine the effects of CycT1 on HIV-1 gene expres-
sion, we used RNA interference against CycT1 to
decrease the protein level of CycT1. RNAi against
mutant CyT1 (mutCycT1) or GFP was used as control.
As shown in Fig. 1A, gene expression from the HIV-1
LTR was upregulated by Tat in a cell line in which Tat
expression was under the control of ponasteron A
(ponA) (Fig. 1A). In this cell line, Tat is stably trans-
fected into 293 cell line, and Tat protein expression is
detected after 12 h of ponA treatment [31]. As
expected, viral gene expression was significantly down-
regulated by depleting CycT1 using siRNA. The effects
of the specific siRNA and its controls (unrelated
siRNA against GFP and mutant siRNA containing
two nucleotide mismatches against CycT1) were also
examined. As shown in Fig. 1B, CycT1 knockdown dra-
matically decreased the CycT1 protein level. However,
to our surprise, the protein level of Tat was simulta-
neously downregulated by CycT1 knockdown. In con-
trast, when control siRNAs were transfected, the Tat
protein levels were not changed. Figure 1C shows the
dose-dependent depletion of Tat, as well as CycT1, by
siRNA against CycT1. No such effect was observed with
control siRNAs, GFP or mutCycT1. In Fig. 1D, the
Jurkat T cell line constitutively expressing Tat [32] was
similarly examined for the effects of CycT1 knockdown.
When CycT1 was knocked down using the CycT1
siRNA, the Tat protein level was also downregulated. In
addition, as previously reported by Chiu et al. [28], the
protein level of CDK9 was not substantially decreased
by CycT1 knockdown (data not shown). No effect was
observed with the control siRNA. In addition, the level
of a control cellular protein, a-tubulin, was not affected
by the various siRNAs (Fig. 1B–D).
Restoration of Tat protein level and Tat-mediated
HIV-1 transactivation by overexpressing
siRNA-resistant CycT1
We then examined the effect of siRNA against CycT1
by overexpressing exogenous CycT1 (‘siRNA-resistant
CycT1’) in which the transduced CycT1 sequence had
been mutated to be resistant to the siRNA. This mutant
CycT1 contains five nucleotide substitutions that render
the mRNA resistant to siRNA-mediated degradation
but do not change the amino acid sequence. Figure 2A
shows that, although siRNA against CycT1 could
downregulate the protein levels of endogenous CycT1
and thus of Tat (lanes 1 and 2), the levels of Tat, as well
as of CycT1, were restored when the siRNA-resistant
CycT1 was transduced (lane 3). No effect was found with
GFP vector (negative control). We also transfected the
siRNA-resistant CycT1 or GFP vector together with
HIV-1LTR-luc (Fig. 2B,), and performed a luciferase
assay in the presence or absence of siRNA against
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CycT1. As expected, the siRNA-resistant CycT1, but
not the control GFP vector, rescued the Tat-mediated
HIV-1 transactivation, consistent with the restoration
of Tat protein levels (compare the 2nd and 3rd columns
in Fig. 2B). These results suggest that CycT1 is involved
in the protein stabilization of Tat as well as its
transcriptional activity.
Effect of CycT1 knockdown on the Tat mRNA level
We further examined the effect of anti-CycT1 siRNA
on the Tat mRNA level. As shown in Fig. 3A, although
anti-CycT1 siRNA dramatically reduced the protein
level of CycT1, the Tat mRNA level was not signifi-
cantly downregulated. In addition, non-specific effects
of transducing siRNA molecules on the Tat mRNA, as
well as its protein levels, were negligible (compare lane 1
with other lanes, and data not shown). Similar results
were observed by quantitative RT-PCR for Tat mRNA
(Fig. 3B). No effect of siRNA against mutCycT1 or
GFP was observed. In addition, the overall effect of
siRNA against CycT1 was assessed by measuring the
cell growth rate. Figure 3C shows that there was no sig-
nificant difference in the relative cell growth rate among
cells treated with control siRNA (GFP), mutant siRNA
(mutCycT1) or siRNA against CycT1 (CycT1), as
Fig. 1. Inhibition of Tat-mediated HIV-1 transactivation by cyclin T1 protein depletion. 293 ⁄ Tat cells were transfected with 100 nM siRNAs
directed against various portions of CycT1 or GFP (control) mRNAs, together with the HIV-1LTR-luc reporter construct expressing the lucifer-
ase gene under the control of the HIV-1 LTR, incubated for 30 h, and treated with ponA (10 lM) for an additional 24 h to induce Tat expres-
sion. (A) Luciferase assay. Cells were harvested and the luciferase activity was measured. The data are means and SD for triplicate
experiments. (B) Immunoblotting of CycT1 and Tat. CycT1 and Tat protein levels were assessed by immunoblotting using specific anti-
bodies. The blot was stripped and re-probed using anti-a-tubulin serum. (C) Downregulation of Tat by CycT1 knockdown. 293 ⁄ Tat cells were
transfected with siRNAs (20–100 nM) targeting CycT1 (left panel), mutCycT1 (mismatched siRNA for CycT1) (center panel) or GFP (right
panel). After 30 h of transfection, cells were either left untreated or treated with ponA (10 lM) and incubated for an additional 24 h. Cells
were harvested, and both the CycT1 and Tat protein levels were assessed as described in (A). Asterisks indicate non-specific bands.
(D) Effect of CycT1 knockdown on the level of Tat protein in Jurkat T cells. Jurkat ⁄ Tat cells were transfected with siRNAs (100 nM). After
48 h of transfection, cells were harvested, and the CycT1 and Tat protein levels were assessed as described in (A).
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evaluated by a cell growth assay utilizing WST-1 dye.
These findings collectively indicate that downregulation
of the Tat protein level by knockdown of CycT1 might
be exerted at the level of protein stabilization. Tat
protein stability was also examined by a pulse-chase
experiment in which CycT1 protein was knocked down
by transfection with anti-CycT1 siRNA (Fig. 3D).
293 ⁄Tat cells were treated with siRNA and cultured in
the presence of ponA to induce Tat expression. The cul-
tured cells were then incubated with medium that was
free of methionine and cysteine, which was subsequently
replaced with medium containing 35S-labeled methio-
nine and cysteine (‘pulse’), followed by cultivation in the
presence of excess amounts of methionine and cysteine
(‘chase’). Cell lysates were prepared from these cell cul-
tures and subjected to immunoprecipitation using the
epitope tag (Flag) present in the Tat protein.
As shown in Fig. 3D, the protein level of Tat was
dramatically decreased by the siRNA against CycT1
(left panel), but no significant change in the Tat pro-
tein level was detected in cells treated with the control
siRNA (right panel). Altogether, these results indicated
that CycT1 protein knockdown affects the Tat protein
stability.
Involvement of proteasome in Tat protein
degradation
The above observations led us to examine whether the
level of Tat protein is determined by proteolytic degra-
dation. Figure 4A shows the extent of downregulation
of Tat protein in the presence of anti-CycT1 siRNA in
the presence of various protease inhibitors. Of these
inhibitors, the proteasome inhibitors including MG132
and lactacystin increased the steady-state level of Tat
protein, but no such effect was seen with other prote-
ase inhibitors such as leupeptin, pepstatin A and apro-
tinin. However, the lysosomal inhibitor NH4Cl showed
a moderate effect. These observations indicate that the
proteasome pathway might be primarily involved in
degradation of Tat protein, and are concomitant with
the siRNA-mediated downregulation of CycT1. How-
ever, the siRNA-mediated CycT1 degradation was not
restored by proteasome inhibitors, presumably because
the CycT1 degradation takes place at the level of its
mRNA by the action of siRNA. No such effects of
proteasome inhibitors were observed in the absence
of siRNA against CycT1 (Fig. 4B).
Discussion
Tat plays an essential role in HIV gene expression and
viral replication [1], and stimulates transcription from
HIV provirus by recruiting P-TEFb through direct
binding with CycT1, a regulatory subunit of P-TEFb
[2–4]. As transcription is a rate-determining step of
viral replication, and Tat is unique in that it specifically
stimulates transcription of viral gene expression, Tat
has been considered to be an appropriate target for
novel anti-HIV therapy. However, none of the anti-Tat
Fig. 2. Restoration of Tat protein and HIV-1 gene expression by
siRNA-resistant CycT1. 293 ⁄ Tat cells were transfected with HIV-
1LTR-luc together with CycT1 siRNA (100 nM) with or without
co-transfection of siRNA-resistant CycT1 or GFP expression vector.
After 30 h of transfection, cells were treated with ponA (10 lM)
and incubated for additional 24 h. CycT1, Tat and GFP protein levels
were assessed by immunoblotting using specific antibodies (A).
Cells were harvested and the luciferase activity was measured (B).
Values are means and SD.
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strategies developed to date, including low-molecular-
mass Tat antagonists [15], dominant-negative Tat
[14,33], anti-Tat single chain intrabodies [9], inhibitory
Tat peptides [16,17,34,35], TAR decoys [11], anti-tat
hammerhead ribozymes [10] or siRNAs against Tat
[12,13,19], have been found to be clinically applicable,
presumably due to lack of specificity or the fact that
Tat action has to be completely abolished in order to
block its transcriptional activity. Similarly, as Tat is a
viral protein and is subject to mutational changes in
accordance with the presence of its inhibitor, new strat-
egies may involve considering host factors such as
CycT1 as molecular targets. Tat is a natively unfolded
or naturally disordered protein, and is rapidly degraded
when expressed alone [36]. A recent report on a tripar-
tite complex formation among CycT1, equine infectious
anemia virus Tat and TAR provided structural insights
on the mutual stabilization of the molecules [37]. Inter-
estingly, the CycT1 protein level is increased when cells
are infected by HIV-1 and when Tat is produced
[38,39], suggesting that the protein stabilities of Tat
and CycT1 depend on each other. We therefore exam-
ined whether the Tat protein level was downregulated
when CycT1 is downregulated. In this study, we found
that, when CycT1 was knocked down, Tat protein was
dramatically destabilized and subsequently degraded by
the proteasome pathway.
Several approaches have been used to block HIV
transcription by targeting CycT1, including the use of
small compounds or mutant proteins that disrupt the
interaction between Tat, TAR and CycT1 [24,30]. In
addition, several CycT1-binding proteins and their
truncated mutants have been examined as potential
inhibitors of Tat transactivation [25,27]. Moreover, Bai
Fig. 3. Effects of CycT1 knockdown on Tat mRNA levels. (A,B) Effects of CycT1 knockdown on Tat mRNA. 293 ⁄ Tat cells were transfected
with siRNAs (100 nM) for 30 h, and treated with ponA (10 lM) to induce Tat expression. After 24 h of ponA stimulation, total RNA was puri-
fied from the cell culture, and subjected to RT-PCR using gene-specific primers (A) or real-time RT-PCR analysis using Tat primer ⁄ probe mix-
tures (B). (C) Effects of CycT1 knockdown on cell growth. 293 ⁄ Tat cells were transfected with siRNAs (100 nM) for 48 or 72 h. Cell viability
was determined by the WST-1 method. No significant effects on cell growth and viability were noted. (D) Tat protein stability depends on
the presence of CycT1. 293 ⁄ Tat cells were treated with siRNAs against CycT1 or mutCycT1 (100 nM each) for 30 h, cultured in the presence
of ponA for 8 h, replaced in a methionine- and cysteine-free culture medium and further cultured for 30 min. The cultured cells were then
incubated in the presence of 35S-labeled methionine and cysteine for an additional 4 h (‘pulse’), followed by cultivation in the presence of
excess amounts (2 mM) of cold methionine and cysteine for 14 h (‘chase’). The cells were lysed, and Tat was immunoprecipitated using
anti-Flag (M2) affinity gel beads and visualized by fluorography to detect radioactivity as described in Experimental procedures. The experi-
ments were repeated, and representative data are shown.
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et al. [26] demonstrated that transduction of anti-
CycT1 intrabodies could render cells resistant to HIV-1
replication by effectively inhibiting Tat-mediated
HIV-1 transactivation. Furthermore, two independent
studies [28,29] reported that siRNA directed to CycT1
successfully downregulated Tat action and HIV-1 viral
replication, although they did not demonstrate acceler-
ated Tat protein degradation. These results support an
essential role for CycT1 in Tat transactivation and
HIV-1 replication.
It was anticipated that downregulation of CycT1
would cause non-specific effects on cell viability or
function given the involvement of P-TEFb in the tran-
scription of many cellular genes [2]. However, other
studies [28,29] demonstrated that knockdown of CycT1
led to inhibition of HIV-1 replication but did not affect
P-TEFb kinase activity and cell viability, as observed
in this study (Fig. 3C). This indicates that a very low
level of P-TEFb kinase activity might be sufficient for
the maintenance of cell viability, or the cells could com-
pensate for lower P-TEFb protein levels by converting
kinase-inactive P-TEFb into active forms [28]. It has
also been reported that, although CycT1 knockdown in
the human monocytic cell line MM6 by small hairpin
RNA inhibited Tat activation, MM6 cell growth was
not affected by the depletion of CycT1 [40]. However,
as induction of substantial numbers of genes associated
with phorbol 12-myristate 13-acetate-mediated stimula-
tion of MM6 and CD4+ T cells is known to require
CycT1 [40,41], downregulation of CycT1 may have
some side effects in such cell lineages. It is possible that
other CycT family proteins such as CycT2a and
CycT2b could functionally substitute for CycT1.
Moreover, as hexamethylene bis-acetamide inducible
protein 1 is known to bind CycT1 at a similar location
as Tat [42], it is possible that hexamethylene bis-aceta-
mide inducible protein 1 protein has been degraded
upon CycT1 knockdown as transcriptional activity was
rescued by the siRNA-resistant CycT1, as demon-
strated in this study (Fig. 2).
We also found that downregulation of Tat protein
could be blocked by certain protease inhibitors,
namely MG132 and lactacystin, which are both protea-
some inhibitors, and to a lesser extent by NH4Cl, a
lysosome inhibitor. It has been reported that the E3
ubiquitin ligase Hdm2 binds to Tat, mediates its poly-
ubiquitylation, and supports HIV-1 transactivation by
Tat [43]. Although we attempted to specify the post-
translational modification of Tat that is responsible for
proteolytic cleavage, we did not obtain reproducible
results, even using proteasome inhibitors. Interestingly,
a recent report by Jadlowsky et al. [30] demonstrated
that a dominant-negative CycT1 mutant that binds to
Tat but cannot support Tat-mediated HIV-1 transacti-
vation leads to degradation of Tat in addition to its
own degradation when transduced into cells. These
Fig. 4. Effects of protease inhibitors on Tat
protein degradation. 293 ⁄ Tat cells were
transfected with CycT1 siRNA (100 nM) for
30 h, and protease inhibitors was added to
the culture together with ponA (10 lM) and
further cultured for 24 h. The cells were
harvested and both Tat and CycT1 protein
levels were analyzed by immunoblotting.
The inhibitors used were MG132 (5 lM),
lactacystin (5 lM), leupeptin (500 lgÆmL)1),
pepstatin A (20 lM), aprotinin (10 lM) and
NH4Cl (5 mM). Immunoblotting was per-
formed on cell cultures with (A) or without
(B) siRNA against CycT1.
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results, together with our findings (Fig. 4), suggest that
is it reasonable to assume that any abortive protein
complex involving Tat and CycT1, but lacking func-
tional activity, is degraded by the proteasome pathway.
However, the distinct roles of various Tat modifica-
tions such as poly- and monoubiquitination required
clarification, and the ubiquitination enzyme(s) need to
be identified. Nevertheless, our findings clearly demon-
strate that downregulation of Tat-mediated HIV-1
transactivation could primarily be due to the downre-
gulation of CycT1, although the possibility of upregu-
lation of Tat action by polyubiquitination remains to
be explored. Thus, reagents that inhibit the interaction




The establishment of a ponA-inducible cell line expressing
Tat has been described previously [31]. In this cell line, Tat
was stably transfected into 293 cells, and the expression of
Tat protein is under the stringent control of ponasteron A
(Invitrogen, Carlsbad, CA, USA), a homolog of the insect
hormone 20-OH-ecdysone. The cells were maintained at
37 C in Dulbecco’s modified Eagle’s medium (Sigma,
St Louis, MO, USA) with 10% fetal bovine serum (Sigma),
500 lgÆmL)1 G418 (Invitrogen) and 450 lgÆmL)1 zeocine.
The Jurkat ⁄Tat T cells, which constitutively express Tat
protein [32], were maintained in RPMI-1640 (Sigma) with
10% fetal bovine serum and G418 (800 lgÆmL)1).
RNA interference and transfection
siRNAs with two thymidine residues (dTdT) at the 3¢ end
were chemically synthesized (Takara Bio, Ohtsu, Japan).
The target sequences were as follows: CycT1, 5¢-UC
CCUUCCUGAUACUAGAA-3¢ (nucleotide positions 347
–365); mutant CycT1, 5¢-UCCCUUCCGUAUACUAGA
A-3¢ [28]; GFP, 5¢-GGCUACGUCCAGGAGCGCACC-3¢.
Underlined residues indicated the sequence that is mis-
matched with respect to CycT1. Transfection of siRNA
into 293 ⁄Tat cells was performed using Lipofectamine 2000
(Invitrogen) as described previously [31]. Jurkat ⁄Tat cells
were transfected using Nucleofector kit V for Jurkat cells
(Amaxa Biosystems, Walkersville, MD, USA) as described
previously [44]. Briefly, 3 · 106 cells were mixed with
100 nm of siRNA in 100 lL of Nucleofector solution V.
These samples were transferred into a transfection cuvette
and subjected to electroporation using program T-14. After
electroporation, cells were immediately transferred to
2.0 mL of culture medium, and cultured in six-well plates
at 37 C for 48 h.
Plasmid construction
The HIV-1 LTR-based luciferase expression plasmid HIV-
1LTR-luc (containing the entire U3 and R sequences of
HIV-1) has been described previously [44,45]. The mutated
CycT1 expression vector, containing five nucleotide substi-
tutions, including T361G, A362C, A364C, A365T and
G366C, that do not change the corresponding amino acid
but render CycT1 resistant to the siRNA, was constructed
using a site-directed mutagenesis kit (QuickChange, Strata-
gene, La Jolla, CA, USA) with pcDNA-CycT1 [31] as a
template and with the following mutagenesis oligonucleo-
tide primer pair: forward, 5¢-CCCTTCCTGATACGCG
CTCTGAGGCTTATTTG-3¢; reverse, 5¢-CAAATAAGC
CTCAGAGCGCGTATCAGGAAGGG-3¢. All constructs
were confirmed by dideoxynucleotide sequencing using an
ABI PRISM Dye Terminator Cycle Sequencing Ready
Kit (Perkin-Elmer, Waltham, MA, USA) on an Applied
Biosystems 313 automated DNA sequencer (Applied Bio-
systems, Foster City, CA, USA).
Immunoblot assays
Immunoblotting was performed as described previously [40].
Briefly, cells were harvested using lysis buffer (25 mm Hepes ⁄
NaOH pH 7.9, 150 mm NaCl, 1.5 mm MgCl2, 0.2 mm
EDTA, 0.3% Nonidet P-40, 1.0 mm dithiothreitol, 0.5 mm
phenylmethylsulfonyl fluoride). After centrifugation at 4 C
for 20 min at 15 000 g, the supernatant proteins were sepa-
rated by SDS-PAGE and transferred to nitrocellulose mem-
brane (Hybond-C, Amersham, Piscataway, NJ, USA). The
membrane was probed using antibodies against Flag (Sigma),
Tat (ZeptoMetrix Co., Buffalo, NY, USA) or CycT1 (Santa
Cruz Biotechnology, Santa Cruz, CA, USA), and immuno-
reactive proteins were visualized by enhanced chemilumines-
cence (SuperSignal, Pierce, Rockford, IL, USA).
Luciferase assay
The luciferase assay using HIV-1LTR-luc was performed as
described previously [46]. The transfected cells were har-
vested and the extracts were subjected to luciferase assay
using the Luciferase Assay System (Promega, Madison,
WI, USA). All experiments were performed in triplicate,
and the data are presented as the fold increase in luciferase
activity (means ± SD) relative to the control for three
independent transfections.
Preparation of mRNA and RT-PCR
Total cellular RNA was prepared from each cell culture
using RNeasy (Qiagen, Valencia, CA, USA). For cDNA
synthesis, 1.0 lg of total RNA was reverse-transcribed using
an oligo(dT) primer and Superscript II reverse transcriptase
Stabilization of Tat protein by cyclin T1 K. Imai et al.
7130 FEBS Journal 276 (2009) 7124–7133 ª 2009 The Authors Journal compilation ª 2009 FEBS
(Invitrogen). The cDNA was then amplified from each
RNA sample using Taq master mix (Qiagen) and gene-spe-
cific primers. The primer sequences for each amplified gene
were: Tat forward, 5¢-GCATCTCCTATGGCAGGAAG-3¢;





number of cycles was chosen to enable linear amplification
of the cDNA under study. The PCR products were sepa-
rated on 1.5% agarose gels and visualized by ethidium bro-
mide staining.
Quantitative real-time RT-PCR was performed as
described previously [31]. The oligonucleotide primers and
probe for Tat were synthesized by Applied Biosystems. The
primer and probe sequences for Tat were 5¢-GGAG
GAGGGTTGCTTTGATAGAG-3¢ (forward) and 5¢-AAA
GCCTTAGGCATCTCCTATGG-3¢ (reverse); probe, 5¢-C
TTCGTCGCTGTCTCCGCTTCTTCC-3¢. The oligonu-
cleotide primers and probe for b-actin genes were pur-
chased from Assays-on-Demand (Applied Biosystems).
Quantitative measurements of each mRNA level were per-
formed in triplicate. The expression levels of test genes were
normalized to the mRNA level of b-actin, as an internal
control, in the same mRNA sample.
Cell proliferation assay
The extents of cell proliferation were evaluated using 2-(4-
iodophenyl)-3-(4-nitrophenyl)-5-(2,4-disufophenyl)-2H-tetra-
zolium (WST-1) (Roche, Indianapolis, IN, USA) according
to the manufacturer’s protocol. In brief, 293 ⁄Tat cells were
transfected with siRNAs in a 96-well plate for 48 or 72 h,
incubated for a further 4 h in the presence of WST-1, and
the level of water-soluble formazan produced was measured
at 450 nm by spectrophotometry.
Labeling of cellular protein with 35S-labeled
amino acid and immunoprecipitation of Tat
After 30 h of cultivation, the cells were transfected with siR-
NA against CycT1 or mutCycT1 (100 nm each), and treated
with ponA for 8 h. The culture was then maintained in
methionine ⁄ cysteine-free medium for 30 min and pulse-
labeled with 200 lCiÆmL)1 of [35S] in vitro Cell Labeling
Mix (GE Healthcare, Piscataway, NJ, USA) containing
35S-labeled cysteine and methionine for 4 h. The cells were
washed quickly twice using NaCl ⁄Pi, and incubated for an
additional 14 h in Dulbecco’s modified Eagle’s medium sup-
plemented with excess methionine and cysteine (2 mm each).
Cells were harvested using lysis buffer (25 mm Hepes ⁄NaOH
pH 7.9, 150 mm NaCl, 1.5 mm MgCl2, 0.2 mm EDTA, 0.3%
NP-40, 1 mm dithiothreitol, 0.5 mm phenylmethylsulfonyl
fluoride) and incubated at 4 C for 20 min with gentle
rotation. The cell lysates were centrifuged at 15 000 g for
20 min. The supernatant was incubated with anti-Flag M2
affinity gel beads (Sigma) for 2 h at 4 C. Immune complexes
were washed three times with 1.0 mL of lysis buffer, and
antibody-bound proteins were dissolved by boiling in 2·
Laemmli sample buffer. After centrifugation at 4 C for
5 min at 15 000 g, the supernatant proteins were separated
by SDS–PAGE and visualized by autoradiography.
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